In Section A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. More participants is going to be enrolled within the determined monotherapy dosign program. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 might be given as "incorporate-on" therapy. In Section https://clinicaleffectivenessofab67902.blazingblog.com/32119797/top-guidelines-of-abbv-744-safety-and-side-effects